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The recent whole-genome scan for breast cancer has revealed the FGFR2 (fibroblast growth factor receptor 2) gene as a
locus associated with a small, but highly significant, increase in the risk of developing breast cancer. Using fine-scale
genetic mapping of the region, it has been possible to narrow the causative locus to a haplotype of eight strongly
linked single nucleotide polymorphisms (SNPs) spanning a region of 7.5 kilobases (kb) in the second intron of the
FGFR2 gene. Here we describe a functional analysis to define the causative SNP, and we propose a model for a disease
mechanism. Using gene expression microarray data, we observed a trend of increased FGFR2 expression in the rare
homozygotes. This trend was confirmed using real-time (RT) PCR, with the difference between the rare and the
common homozygotes yielding a Wilcox p-value of 0.028. To elucidate which SNPs might be responsible for this
difference, we examined protein–DNA interactions for the eight most strongly disease-associated SNPs in different
breast cell lines. We identify two cis-regulatory SNPs that alter binding affinity for transcription factors Oct-1/Runx2
and C/EBPb, and we demonstrate that both sites are occupied in vivo. In transient transfection experiments, the two
SNPs can synergize giving rise to increased FGFR2 expression. We propose a model in which the Oct-1/Runx2 and C/
EBPb binding sites in the disease-associated allele are able to lead to an increase in FGFR2 gene expression, thereby
increasing the propensity for tumour formation.
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e108. doi:10.1371/journal.pbio.0060108
Introduction
FGFR2 (ﬁbroblast growth factor receptor 2) plays a pivotal
role both in mammary gland development and in cancer [1].
The FGFR2 gene encodes a transmembrane tyrosine kinase
and can function as a mitogenic, motogenic, or angiogenic
factor, depending on the cell type and/or the microenviron-
ment. Mammary epithelial cells express FGFR2IIIb (including
alternatively spliced exon 9), which binds FGF-7 and FGF-10,
which are normally expressed by surrounding mesenchymal
cells. Mouse models of mammary carcinogenesis have long
established the FGF signalling pathway as a major contributor
to tumorigenesis [2], and a mouse mammary tumour virus
(MMTV) insertional mutagenesis screen for genes involved in
breast cancer has identiﬁed FGFR2 and FGF10 [3]. In human
breast cancer, the expression of FGFR2 has long been known
to be elevated in estrogen receptor (ER)–positive tumours [4],
which has been conﬁrmed by data analysis performed with
the ONCOMINE 3.0 array database [5,6]. Likewise both FGF-7
and FGF-10 have been found to be expressed in a proportion
of breast cancers [7, 8]. Functional studies in cell lines have
implicated FGFR2 as playing a role in tumourigenesis, with an
alternative splicing in the C-terminal domain of FGFR2
giving rise to a more strongly transforming isoform [9].
However, as yet, nothing is known about the mechanism by
which FGFR2 acts as a risk factor in predisposition to breast
cancer.
We examined the functional implication of genetic
variation in the FGFR2 haplotype associated with suscepti-
bility to breast cancer and we demonstrate increased gene
expression for the risk allele.
Results
Two independent studies have identiﬁed FGFR2 as risk
factor in breast cancer [10,11]. We have shown that in
Europeans, the minor disease-predisposing allele of FGFR2 is
inherited as a haplotype of eight single nucleotide poly-
morphisms (SNPs) covering a region of 7.5 kb within intron 2
of the gene [10] (Figure 1), in a haplotype block with no
linkage disequilibrium with the coding region of the gene.
Microarray gene expression analysis on the Nottingham City
Hospital cohort, using both the Agilent [12] and the Illumina
[13] platforms, indicated that FGFR2 is expressed at higher
levels by tumours that are homozygous for the minor alleles
than by those with the common alleles (Wilcox p , 0.05).
Analysed tumours were all diploid for this region based on
array-comparative genome hybridization data [14]. This
correlation was independent of either ER expression or p53
mutation status of the cells. Quantitative TaqMan PCR
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analysis conﬁrmed a signiﬁcant increase in FGFR2 expression
in rare homozygotes, as compared to common homozygotes
(Wilcox p¼ 0.028) (Figure 2). We also examined expression of
the FGFR2 ligands FGF-7, FGF-10, and FGF-22, which are
usually produced by the surrounding stroma, in 45 normal
breast samples as well as the microarray data on tumours, but
we found no correlation with genotype. Furthermore, FGFR2
displays a very complex splicing pattern with the most
commonly expressed variants of the N terminus of the gene
either including exons 1, 2, and 3 or including exons 1 and 2,
but lacking exon 3. Again, no correlation was observed
between genotype and the presence or absence of exon 3.
Thus, the risk genotype correlates with FGFR2 expression
itself, rather than affecting its function through receptor-
ligand interactions.
This correlation suggests that the functional SNPs map to a
regulatory region within the gene, possibly by altering one or
more transcription factor binding sites. Interactions between
proteins from nuclear extracts and DNA were examined for
the eight most strongly disease-associated alleles (Figure 1).
Two of these candidate functional SNPs showed distinct
binding patterns in electrophoretic mobility shift assays
(EMSA). The common allele of rs7895676 (FGFR2–33) formed
strong protein–DNA complexes with nuclear extracts from
the breast carcinoma cell lines HCC1954 (Figure 3A) and
PMC42 and from HeLa cells (unpublished data), whereas no
binding was detected on the minor allele. Competition
studies and supershift experiments identify the bound
protein as C/EBPb (Figure 3A). We note that the FGFR2–33
sequence has considerable homology to the C/EBPb binding
site from the interleukin 6 (IL-6) promoter [15] (Figure 3C).
The heterogeneity of the observed protein–DNA complexes is
most likely due to the presence of multiple C/EBPb isoforms.
For rs2981578 (FGFR2–13), both alleles give rise to a strong
protein–DNA complex in HCC1954 cell extracts. However, a
second more slowly migrating complex was only seen on the
rarer genotype (Figure 3B). Interestingly, both alleles are able
to compete for both bands, suggesting that the formation of
the upper complex depends on the presence of the lower
complex. Inspection of the FGFR2 DNA indicated the
presence of a perfect octamer binding site immediately
adjacent to the SNP, while the SNP itself lay within a
sequence with homology to Runx binding sites (Figure 3C).
Competition studies and incubation with speciﬁc antisera
shows that both alleles bind Oct-1, while only the minor allele
binds Oct-1 and Runx2 in HCC1954 nuclear extracts (Figure
3B), as well as in PMC42 cells (Figure S1).
To establish whether or not these sites were occupied in
vivo, we carried out chromatin immunoprecipitation (ChIP)
experiments using the ERþ breast cancer cell lines HCC70
and T47D, which are homozygous for the minor and the
common FGFR2 alleles, respectively. In addition, we con-
Figure 1. Diagram of the FGFR2 Gene
Genetic linkage is taken from HapMap, and the positions of the eight candidate SNPs (red lines) within intron 2 are indicated. The two SNPs for which
data are presented in this study are shown in green. Red circle: original tagging SNP rs2981582.
doi:10.1371/journal.pbio.0060108.g001
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Author Summary
Recently, a number of whole-genome association studies have
identified genes that predispose individuals to common diseases
such as cancer. The challenge now is to understand how the
identified risk loci contribute to disease, since the majority of these
loci are located within introns (which are discarded after tran-
scription) and intergenic regions, and therefore do not change the
coding region of nearby genes. This manuscript describes how two
single–base pair changes in intron 2 of the FGFR2 (fibroblast growth
factor receptor 2) gene, ‘‘the top hit’’ of the breast cancer
susceptibility study, exert their function. We find that the changes
alter the binding of two transcription factors and cause an increase
in FGFR2 gene expression, thus providing a molecular explanation
for the risk phenotype. This is the first functional study, to our
knowledge, of the risk loci identified for breast cancer in a whole-
genome scan and demonstrates that these studies can be used as
valid starting points for studying the underlying biology of cancer.
ﬁrmed that these cell lines were diploid for the FGFR2 locus
and only expressed the epithelial-speciﬁc isoform FGFR2IIIb
[16]. The ChIP analysis was carried out on homozygous cell
lines, because the SNP overlapping the C/EBPb site lies in a
repetitive region for which the different alleles could not be
distinguished reliably by TaqMan PCR. A representative
experiment is shown in Figure 3D. After Runx2-precipitation,
the FGFR2–13 site is enriched 2-fold for the minor versus the
common allele, conﬁrming the EMSA results. Western
blotting indicated that Runx2 is more abundant in T47D
cells, thus conﬁrming that differential ChIP in the two cell
lines is due to the presence of the SNP. Oct-1 precipitation
did not yield enrichment of FGFR2–13 for either allele. The
Oct-1 epitope may either be sequestered within a higher-
order complex or the antisera used do not work efﬁciently in
a ChIP assay. On the FGFR2–33 site, we observed a 1.7-fold
enrichment of C/EBPb binding on the common allele. In
addition, we observe that C/EBPb can also bind to the minor
allele, although less efﬁciently. Both cell lines contain
comparable amounts of C/EBPb as judged by Western
blotting (unpublished data). In conclusion, both the C/EBPb
and the Runx2 binding sites are occupied in vivo.
To test whether differential protein binding could alter the
ability of the susceptibility alleles to activate transcription, we
multimerised oligonucleotides overlapping both the Oct-1/
Runx2 and the C/EBPb binding sites, cloned these in both
orientations upstream of the luciferase reporter gene in
pGL3Enh (Figure 4A), and assayed them in three breast
cancer cell lines (PMC42, HCC70, and T47D). Transfections
were carried out in triplicate and repeated at least twice for
each cell line. A representative transfection into HCC70 cells
is shown in Figure 4B (see Figure S2 for PMC42 and T47D). In
all three cell lines tested, the minor allele at the Oct-1/Runx2
site stimulated transcription 2- to 5-fold over the common
allele, independent of orientation, with the average being just
above a 3-fold increase (p , 0.01). In contrast, the minor and
common alleles of the multimerised C/EBPb binding site did
not show a consistent pattern of activation relative to each
other. It varied with the cell lines and the orientation in
which constructs were tested. Nevertheless, relative to the
parental vector, the common allele always showed transcrip-
tional activation. Compared to the common allele, the minor
allele was either not signiﬁcantly different or gave rise to a
smaller degree of activation. However, in the latter case, the
rare allele still activated transcription signiﬁcantly above the
enhancer-only construct (p , 0.01). Presumably this reﬂects
the fact that the minor allele of FGFR2–33 still binds C/EBPb
above background levels in vivo (Figure 3D). By comparing
the two different sites, we found that for Oct-1/Runx2 the
minor allele was more active, while for C/EBPb, the common
site yielded higher levels of transcription in the majority of
experiments. Hence their effects were opposing. We there-
fore assayed a synthetic construct consisting of single sites for
C/EBPb, Oct-1, and Runx2. In this arrangement, the effect of
Oct-1/Runx2 clearly predominates, with the minor allele
expressed at higher levels, reﬂecting the situation at the
endogenous locus.
Discussion
The data presented here lead us to conclude that the Oct-1/
Runx2 binding site is the dominant determinant of differ-
ential expression between the common and minor haplotypes
of FGFR2. Although Runx2 is a master regulator of osteoclast-
speciﬁc transcription, Runx2 also plays an important role in
mouse mammary gland–speciﬁc gene expression [17], where
Runx2 activity is dependent on Oct-1 [18]. It is intriguing to
note that in bone cells, overexpression of constitutively active
FGFR2 leads to increased levels of Runx2 mRNA [19]. FGFR2
in turn is responsive to Runx2 in osteoclasts via the OSE2
(osteoclast speciﬁc element 2) in its promoter [20]. The
description here of a Runx2 site in the FGFR2 gene that is
occupied in breast cancer cells, suggests that in the presence
of the minor genotype, a similar positive feedback loop could
also be established in breast cells. The role of the C/EBPb
binding site on FGFR2 expression has been harder to deﬁne.
The common allele binds C/EBPb more tightly and activates
transcription more strongly in most cases. Yet in a composite
construct the activity of the Oct-1/Runx2 site dominates. This
may be because C/EBPb can directly bind to and synergize
with Runx2 [21]. Thus, on the minor genotype, Oct-1 and
Runx2 are present and able to synergize with the C/EBPb
bound (as suggested from the ChIP experiments), giving rise
to higher levels of transcriptional activation. This is
supported by the ﬁnding that a single copy of the C/EBPb/
Oct-1/Runx2 site gives rise to higher levels of activation than
a concatemerized Oct-1/Runx2 site with six potential inter-
action sites (Figure 4A). A potential role for C/EBPb in
tumour etiology is supported by the observation that C/EBPb
is highly overexpressed in malignant human breast cells [22].
In conclusion, our evidence supports Oct-1/Runx2 as the
probable primary determinant of activity, with C/EBPb
contributing to the risk haplotype.
The increased risk in breast cancer conferred by the FGFR2
allele is predominant for ERþ breast tumours, while there is
Figure 2. Correlation of FGFR2 Expression in Breast Tumours with
Genotype
Quantitative RT-PCR was carried out using a probe targeting the 3’ UTR
of FGFR2.
doi:10.1371/journal.pbio.0060108.g002
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no signiﬁcant increase in risk for ER– tumours. Genome-wide
analysis of ER binding sites has revealed three potential ER
binding sites within the FGFR2 gene [23], and ER and Oct-1/
Runx2 may cooperate to increase gene expression. This is
consistent with ﬁndings that Oct and ER sites often cluster
[23]. The risk conferred by the disease-associated genotype
may also depend on the signalling potential of FGFR2 in ERþ
cells. FGF-7 is over-expressed only in breast tumours that are
ERþ [8]. Elevated levels of FGFR2 may then contribute to the
establishment of an autocrine signalling loop, reducing the
cell’s propensity to undergo apoptosis [24]. Alternatively,
paracrine signalling by mesenchymally or luminally derived
FGF-7 or -10 on cells overexpressing FGFR2 may also drive
cell proliferation.
To our knowledge, this is the ﬁrst functional study on the
risk loci recently identiﬁed for breast cancer. Our study
demonstrates that SNPs identiﬁed by whole-genome scans can
be used a valid starting points for studying the underlying
biology of cancer. SNPs identiﬁed in other whole-genome
scans for the genetic basis of complex diseases also primarily
map in intronic or intergenic regions. Our observation that an
identiﬁed SNP regulates the expression of the risk allele is
therefore likely to be a common theme. Breast cancer is one of
the most common cancers in the developed world. The FGFR2
minor allele carries only a small increase in risk and acts as part
of a spectrum of risk factors. However, it has a highminor allele
frequency (0.4), and FGFR2 is therefore likely to contribute to
the incidence of breast cancer in many individuals.
Figure 3. Protein–DNA Interactions at FGFR2–33 and FGFR2–13 In Vitro and In Vivo
EMSAs on (A) FGFR2–33 and (B) FGFR-13 minor (m) and common (c) alleles, using 5 lg (FGFR2–33) and 2 lg (FGFR2–13) of HCC1954 nuclear extracts.
Competitor oligonucleotides (minor, common, and ER as negative control) and antisera are indicated above each lane.
(C) Alignment of the sequence around FGFR2–33 with binding site of C/EBPb in the IL-6 promoter [15] and of FGFR2–13 with the Oct/Runx site in the b-
casein gene [18]. The SNP is shown in red and the allele binding the transcription factor is shown.
(D) ChIP assays for FGFR2–13 and FGFR2–33. Enrichment for the minor (HCC70–/–) and the common (T47Dþ/þ) genotype is given relative to a negative
control (TRXR2, located on 22q11.2) after normalisation against rabbit IgG.
doi:10.1371/journal.pbio.0060108.g003
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Materials and Methods
Genotyping. DNA from the 170 tumour samples was genotyped
using a ﬂuorescent 59 exonuclease assay (TaqMan) and the ABI PRISM
7900 SequenceDetection Sequence (PE Biosystems) in 384-well format.
Duplicate samples were included to assess concordance and quality of
genotyping. The genotyping assay was designed for rs2981582, which
tags the whole haplotype block associated with the disease [10].
Analysis of FGFR2 gene expression. Analysis was performed on
total RNA from breast tumour cases. cDNA was prepared with the
TaqMan Reverse Transcription Reagents kit (Applied Biosystems)
using random hexamers, according to the manufacturer’s instruc-
tions. Expression levels were determined using a TaqMan Gene
Expression Assay (Hs00240796_m1, Applied Biosystems) and nor-
malized to four different housekeeping genes.
Statistical analysis. To assess whether there were signiﬁcant
statistical differences between the expression levels across the
genotype groups we used a Wilcoxon test, ﬁtted using the R statistical
framework. Elsewhere, Student’s t-tests were carried out using
Microsoft Excel.
Cell lines and cell culture. Breast cancer cell lines HCC1954,
HCC70, T47D, and PMC42 were cultured in RPMI supplemented with
10% foetal calf serum and penicillin/streptomycin under standard
conditions. These cell lines have been characterised extensively, and
karyotypes are available at the Cancer Genomics Program of the
University of Cambridge (http://www.path.cam.ac.uk/;paweﬁsh).
EMSAs. Small-scale nuclear extracts and bandshifts were carried
out as previously described [25], except that Complete Protease
Inhibitors (Roche) were used. In supershift experiments, polyclonal
antisera against Oct-1 (sc-232x), Runx2 (sc-10758x), and C/EBPb (sc-
150x) were obtained from Santa Cruz Biotechnology, Inc and up to 8
ll were added per reaction, unless otherwise stated. Oligonucleotides
(Table S1) were annealed to complementary strands, and the
resulting BamHI overhangs ﬁlled in with Klenow enzyme, using
radiolabelled [a32P]dCTP (GE Healthcare, UK).
ChIP. Primers were designed using Primer Express (Applied
Biosystems) and Lasergene (DNA Star) to amplify regions of up to 100
bp comprising the SNPs of interest, plus one negative control (region of
the genome not suspected to bind any of the transcription factors of
interest) (Table S1). PCR ampliﬁcation was carried out with Power
SYBRGreenMastermix (Applied Biosystems), using 2 ll of precipitated
and puriﬁed DNA as described [23]. The antisera were as in the EMSAs,
except for C/EBPb, which was a polyclonal serum from Abcam, UK.
Plasmid construction and luciferase assays. The pGL3-Enhancer
vector (Promega) was linearized with BglII and re-circularised in the
presence of annealed oligonucleotides (Table S1). All constructs were
veriﬁed by sequencing. DNA was prepared using Qiagen kits and
transfected into tumour cell lines cultured in 24-well plates. Per well,
500 ng of reporter and 100 ng CMV-b-galactosidase plasmid were
tranfected using 2 ll of Fugene 6 (Roche), harvested 36–48 h later and
extracts prepared using 100 ll Promega lysis buffer. Luciferase and b-
galactosidase activity in 25 ll was measured using Promega reagents.
Results are given as ratios of luciferase over b-galactosidase activity.
Supporting Information
Figure S1. EMSA on the Common and Minor Allele of FGFR2–13
using PMC42 Nuclear Extracts
5 lg of nuclear extract and 8 ll of a-Oct-1 (ab15112), a-Runx2
(ab11906), and a-C/EBPb (ab32358) from Abcam, UK, were included
as shown above the lanes. ns, non-speciﬁc binding.
Found at doi:10.1371/journal.pbio.0060108.sg001 (3.04 MB AI).
Figure S2. Transcriptional Activation by the Minor and Common
Alleles of Oct-1/Runx2 and C/EBPb binding sites of FGFR2
(A) Diagram of the concatemerised binding sites cloned into pEnh.
These constructs were assayed in the cell lines.
(B) PMC42 and (C) T47D cells. Results are given as fold increase over
pEnh activity. CMV-b-galactosidase served as transfection control.
The binding sites are indicated beneath each data point, with [Oct/
Runx] and [C-EBP] being trimerized, while [C/O/R] contained only a
single binding site for C/EBPb, Oct-1, and Runx2.
Found at doi:10.1371/journal.pbio.0060108.sg002 (238 KB PPT).
Table S1. Oligonucleotides Used in This Study.
Sequences in brackets show the two alleles (common/minor) of SNPs.
Found at doi:10.1371/journal.pbio.0060108.st001 (50 KB DOC)
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